Michigan State University | Department of Neurology
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,000 participants in 2 patient groups
Loading...
Central trial contact
There will be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal